Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > COMMENTARY
COMMENTARY
- Some Pharma Makers Leery of Further Cut into Off-Patent Brands in Japan
April 3, 2023
- Revision of Guidelines on Drone Drug Deliveries Expected by March-End: Will Powerful Meds Be OK'ed?
March 17, 2023
- FY2024 Pricing Reform Likely to Focus on “Balance” between Rewarding Innovation and Optimizing LLP Prices
February 6, 2023
- LDP Expects to Finalize Tax Reform Plan This Week; Will It Expand R&D Credit System?
December 13, 2022
- Japan Should Hone Emergency Approval Scheme Based on Xocova Example
November 28, 2022
- Pharma Industry Stays Pat on “No” to Off-Year Plan, Why Not Going for Trade-Off?
November 22, 2022
- Pharma Industry Faces Hurdles in Getting Medical Circle to Accept Softer Drug Price Cut Plan
September 28, 2022
- Delving into Potential Implications of Envisaged Price Revision Overhaul
September 12, 2022
- Generic Industry Has High Hopes on New Expert Panel; Will Its Recommendations Ease Impact of Annual Re-Pricing?
September 9, 2022
- Tussle in Japan Diabetes Market Heating Up; BI and Sumitomo Nip and Tuck for No. 1 Slot
August 29, 2022
- Launch of New Expert Panel Nears, How Can It Make Its Proposal Productive?
August 25, 2022
- Pharma Eyes Riveted on JMA’s Stance on Off-Year Revision as New Chief Builds Ties with Govt
August 22, 2022
- Govt Should Examine Challenges with Emergency Approval Scheme Exposed by Shionogi Pill Review
July 25, 2022
- Japan Set to Build Legal Framework for Health Data Use as Initiative Enshrined in Honebuto 2022
July 25, 2022
- Japan Should Accelerate Debate on Legalizing Cannabis-Derived Drugs for Refractory Epilepsies
June 27, 2022
- New Zero Premium Rule Applied to 6 Drugs Since April Rollout, Is It Incentivizing Cost Disclosure?
June 2, 2022
- Foreign Pharma Growing Vocal against Japan’s Pricing Policy, Flags Return of Drug Lag
May 10, 2022
- SCARDA Now Up and Running: Will It Lead to a Recovery in Japan’s Ability to Develop Vaccines?
April 22, 2022
- Ukraine War Sheds Light on Vulnerabilities in Pharmaceutical Supply Chains in Emergencies
April 19, 2022
- Drug Makers Forced to Make Tough Decisions on AG Strategies: Licensing Profits or Losses on Early G1 Cuts?
April 8, 2022
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…